Inspira Technologies has secured a second US patent approval for its VORTX orbiting blood oxygenation delivery system, a key component of the INSPIRA ART device.

This approval brings the total number of new claims for the technology to 32.

The VORTX system is designed to oxygenate blood without the use of fibre membranes, which could revolutionise the medical field by reducing blood damage and associated costs.

Traditional fibre technologies for blood oxygenation can significantly damage blood cells, as they force blood through multiple fibre layers, creating turbulence, friction, and shear forces.

The high resistance of the fibre fabric to blood flow also creates pressure differences that can lead to severe blood component damage, including haemolysis, white blood cell damage, and blood clotting.

Inspira Technologies CEO Dagi Ben-Noon said: “We view this as another major leap forward in blood oxygenation technologies, representing another crucial milestone highlighting the core technological capabilities of the INSPIRA ART.”

INSPIRA ART is designed to support the 20 million patients in intensive care units with respiratory failure every year, a majority of whom depend on mechanical ventilators.

It helps maintain stable oxygen saturation levels without requiring ventilators.

Inspira Technologies OXY received approval from the Israeli Ministry of Health for its INSPIRA ART100 system in July 2024, marking a milestone in its efforts to commercialise its medical technology.

It also received 510(k) clearance from the US Food and Drug Administration (FDA) for cardiopulmonary bypass procedures and Israeli AMAR certification for both extra-corporeal membrane oxygenation and cardiopulmonary bypass procedures.

Inspira Technologies developed the INSPIRA ART with adaptive blood monitoring and oxygenation technology.

This system is designed to rebalance oxygen saturation levels in patients, potentially allowing them to remain awake during treatment and reducing reliance on invasive mechanical ventilation systems that necessitate intubation and medically induced coma.

"Inspira gains new US patent approval for blood oxygenation system" was originally created and published by Medical Device Network, a GlobalData owned brand.

The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.